More Positive Phase IIa Data May Have Vertex CF Drug On Registration Path
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech will seek to win approval in CF patients with G551D mutation, then demonstrate broader application within the disease.
You may also be interested in...
EMD Serono Buys $19M Seat At MS Society’s Research Table
Unlike some other industry/charity couplings, pharma foots the VC bill.
EMD Serono Buys $19M Seat At MS Society’s Research Table
Unlike some other industry/charity couplings, pharma foots the VC bill.
With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene
Disease-oriented foundations and cash-strapped biotechs are increasingly seeking common ground: as more becomes known about the mechanisms by which a given disease operates, foundation boards are finding more opportunities to fund promising start-ups and established biotechs.